Anti-Ige monoclonal antibody therapy for the treatment of patients with chronic rhinosinusitis: a multi-disciplinary pra
- PDF / 258,756 Bytes
- 1 Pages / 595.276 x 793.701 pts Page_size
- 67 Downloads / 143 Views
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
MEETING ABSTRACT
Open Access
Anti-Ige monoclonal antibody therapy for the treatment of patients with chronic rhinosinusitis: a multi-disciplinary practice review Shaun J. Kilty1,2,3*, Andrea Lasso1, Stephanie Santucci4, William Yang3,4 From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2014 Ottawa, ON, Canada. 23-26 October 2014 Background Several treatment options have been described for chronic rhinosinusitis (CRS), yet many patients remain poorly responsive to medical and surgical therapy. Recently, antiIgE monoclonal antibody has emerged as a potential therapy for CRS. However, to date evidence for its efficacy in this patient population is sparse. The purpose of this study is to evaluate the clinical effect of anti-IgE monoclonal antibody therapy for patients with recalcitrant CRS and asthma treated in a multi-disciplinary clinic. Methods A review of the charts for the 194 patients on anti-IgE monoclonal antibody therapy was performed. 20 patients diagnosed with CRS with poorly controlled disease having failed surgical and/or medical therapy were identified. Data extraction targeted demographic details, asthma, environmental allergy and CRS specific disease related data. For data analysis, for nonparametric data the MannWhitney test was used and for binary data Fisher’s exact test was used. Results Mean age of the cohort was 49 years (range 33-67); eleven patients were male. Mean IgE level was 331.14 IU/ml (57.54-1338.96 IU/ml). Mean treatment duration was 17 (3-71) months. The most common skin prick test positive environmental allergens were dust mite (100%) and cat (65%). 75% of patients had CRS with polyps. Six patients (30%) had AERD. The mean polyp score decreased from 1.8 to 1.0 (p=0.106). Patient olfaction improved in 11 patients (55%) with therapy. Two patients 1 The Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, Ottawa, ON, Canada Full list of author information is available at the end of the article
on chronic prednisone treatment were able to discontinue this treatment. None of the patients progressed to require surgical treatment.
Conclusions Anti-IgE monoclonal antibody therapy allowed for clinical CRS disease control in this cohort of patients with severe and recalcitrant CRS. A well-designed clinical trial is needed to further assess the efficacy and safety of this treatment in the CRS population. Authors’ details 1 The Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, Ottawa, ON, Canada. 2Ottawa Hospital Research Insitute (OHRI), Ottawa, ON, Canada. 3The University of Ottawa, Ottawa, ON, Canada. 4Allergy and Asthma Research Centre, Ottawa, ON, Canada. Published: 18 December 2014
doi:10.1186/1710-1492-10-S2-A24 Cite this article as: Kilty et al.: Anti-Ige monoclonal antibody therapy for the treatment of patients with chronic rhinosinusitis: a multi-disciplinary practice review. Allergy, Asthma and Clinical Immunology 2014 10(Suppl 2):A24.
Submit your next manuscript to Bi
Data Loading...
